Tonix Pharmaceuticals to Present at the First Global Life Sciences Conference in Warsaw, Poland on September 17, 2013

Marketwired

NEW YORK, NY--(Marketwired - September 12, 2013) - Tonix Pharmaceuticals Holding Corp. (TNXP), a development stage specialty pharmaceutical company, today announced that it will present at the First Global Life Sciences Conference in Warsaw, to be held at the Warsaw Stock Exchange in Warsaw, Poland on September 16-17, 2013.

Seth Lederman, M.D., Chief Executive Officer, will provide a corporate update on Tuesday, September 17 at 9:50 am Central European Summer Time / 3:50 am Eastern Time. A live webcast of the presentation can be accessed in the Investors section of the Tonix website at www.tonixpharma.com, or through the following link:

http://www.wdmcapital.com/en/strony/lsc/live_webcast.html

An archived version of this webcast will be available until October 17, 2013 in the Investors section of www.tonixpharma.com.

One-on-one meetings with Tonix management may be arranged by contacting Wojciech Grzegorczyk at wojciech.grzegorczyk@wdmsa.pl or by phone at +48 784 094 599.

WDM Capital, a prominent small cap investment bank in Central and Eastern Europe, is organizing the conference in partnership with the Warsaw Stock Exchange and Deloitte. For more information, visit http://lscwarsaw.com.

About Tonix Pharmaceuticals Holding Corp.
Tonix is developing innovative prescription medications for challenging disorders of the central nervous system. The Company seeks to address conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among patients and physicians. Tonix's lead pharmaceutical candidate, TNX-102 SL, targets central pain. Fibromyalgia is a central pain syndrome, and central pain is a component of post-traumatic stress disorder. Tonix applies its core technology toward the treatment of central pain by improving the ability to experience restorative sleep. To learn more, please visit www.tonixpharma.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. These forward-looking statements are based on TONIX's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. TONIX does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K filed with the SEC on March 11, 2013 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.

Contact:


Tonix Pharmaceuticals Holding Corp.
Leland Gershell
Chief Financial Officer
(212) 980-9155 x104
leland.gershell@tonixpharma.com

Investor Relations:
Dian Griesel Int'l.
Cheryl Schneider
(212) 825-3210
cschneider@dgicomm.com

Public Relations:
Dian Griesel Int'l.
Susan Forman or Laura Radocaj
(212) 825-3210
sforman@dgicomm.com
lradocaj@dgicomm.com
View Comments (0)